Microbiome in Atopic Dermatitis Under Systemic Therapy
Recruiting · NCT05099315 · Observational (researchers observe without assigning treatment) · Lead sponsor: Charite University, Berlin, Germany
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The skin microbiome plays a role in the pathogenesis of atopic dermatitis. However, it is unclear whether the range of microbiota on the skin is the cause or consequence of atopic skin inflammation. The influence of new systemic therapies for the treatment of moderate to severe atopic dermatitis (such as biologics or Janus kinase inhibitors) on the skin microbiome is largely unknown. The main aim of this scientific exploratory study is to investigate whether and how the skin microbiome changes in patients with moderate to severe atopic dermatitis during systemic therapy. This not only allows new hypotheses to be generated on the pathogenesis of atopic dermatitis, but also new objective scales for the severity of atopic dermatitis can be developed.
Who can take part
Inclusion criteria
- Patients with moderate to severe atopic dermatitis
- Indication for systemic therapy
Exclusion criteria
- Patients under 18 years of age upon introducing systemic therapy
- Pregnant and lactating women
Where it is running
1 location listed.
- Dpt of Dermatology and Allergology, Charité - Universitätsmedizin Berlin - Berlin, State of Berlin, Germany